Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. 2 July 2019. Adam Saltman.

Executive Summary

A mere two dozen quality-related warning letters were sent by the US FDA to device-makers in calendar year 2018 – the fewest ever issued to companies since the agency's Quality System Regulation came into force 23 years ago. See why FDA medical officer Adam Saltman believes the "big hammer" of enforcement isn't always needed.

"Using the big hammer [of enforcement] isn't necessary all the time. A lot of times there may an initial recommendation for a warning letter, but it ends up getting interpreted into an untitled letter or even a regulatory meeting to take care of the problem, the general idea being that a warning letter may not be necessary in all circumstances." – Adam Saltman, medical officer, the US FDA device center's Office of Product Evaluation and Quality

Click here for a free trial of Medtech Insight

 

Related Content

Topics

UsernamePublicRestriction

Register

MT125312

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel